Literature DB >> 30352332

Quantifying the societal cost of methamphetamine use to Australia.

Robert J Tait1, Steve Whetton2, Marian Shanahan3, Kimberly Cartwright4, Anna Ferrante5, Dennis Gray4, Sharlene Kaye6, Rebecca McKetin4, Ken Pidd7, Alison Ritter3, Ann Roche7, Steve Allsop4.   

Abstract

Globally, there are increasing concerns about the harms associated with methamphetamine use. This paper i) reports on the results of a cost-of-illness (CoI) study that quantified the social costs associated with methamphetamine use in Australia and, ii) drawing on examples from this study, critically examines the general applicability of CoI studies for the alcohol and other drug field. A prevalence approach was used to estimate costs in 2013/2014, the most recent year for which reasonably comprehensive data were available. The value selected for a statistical life-year in our central estimate was AUD 281,798. Other costs were estimated from diverse sources. Total cost was estimated at AUD 5023.8 million in 2013/14 (range, AUD 2502.3 to AUD 7016.8 million). The greatest cost areas were crime including costs related to policing, courts, corrections and victims of crime (AUD 3244.5 million); followed by premature death (AUD 781.8 million); and, workplace costs (AUD 289.4 million). The social costs of methamphetamine use in Australia in 2013/14 are high, and the identification of crime and premature mortality as the largest cost areas is similar to USA findings and represents important areas for prevention and cost remediation. However, caution is required in interpreting the findings of any CoI study, as there is uncertainty associated with estimates owing to data limitations. Moreover, CoI estimates on their own do not identify which, if any, of the costs are avoidable (with drug substitution being a particular problem) nor do they shed light on the effectiveness of any potential interventions. We also recognise that data limitations prevent some costs from being estimated at all.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cost-of-illness; Health economics; Methamphetamine; Morbidity; Mortality

Mesh:

Substances:

Year:  2018        PMID: 30352332     DOI: 10.1016/j.drugpo.2018.08.015

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  8 in total

1.  Macula and optic disk features in methamphetamine and crystal methamphetamine addicts using optical coherence tomography.

Authors:  Monireh Mahjoob; Ali-Reza Maleki; Farshad Askarizadeh; Samira Heydarian; Tahereh Rakhshandadi
Journal:  Int Ophthalmol       Date:  2022-02-21       Impact factor: 2.029

2.  Development of Goal Management Training+ for Methamphetamine Use Disorder Through Collaborative Design.

Authors:  Alexandra C Anderson; Alex H Robinson; Eden Potter; Bronte Kerley; Daphne Flynn; Dan I Lubman; Antonio Verdejo-García
Journal:  Front Psychiatry       Date:  2022-04-25       Impact factor: 5.435

3.  Neurocognitive Empowerment for Addiction Treatment (NEAT): study protocol for a randomized controlled trial.

Authors:  Hamed Ekhtiari; Tara Rezapour; Brionne Sawyer; Hung-Wen Yeh; Rayus Kuplicki; Mimi Tarrasch; Martin P Paulus; Robin Aupperle
Journal:  Trials       Date:  2021-05-07       Impact factor: 2.279

Review 4.  A Narrative Review of the Recent 'Ice' Epidemic: An Australian Perspective.

Authors:  Konrad Pisarski
Journal:  Subst Abuse       Date:  2021-04-21

5.  Protocol for the methamphetamine approach-avoidance training (MAAT) trial, a randomised controlled trial of personalised approach bias modification for methamphetamine use disorder.

Authors:  Joshua B B Garfield; Hugh Piercy; Shalini Arunogiri; Dan I Lubman; Samuel C Campbell; Paul G Sanfilippo; Jeff Gavin; Malcolm Hopwood; Eli Kotler; Suzanne George; Goke Okedara; Lara R Piccoli; Victoria Manning
Journal:  Trials       Date:  2021-01-06       Impact factor: 2.279

6.  Protocol for a cluster randomised crossover pilot trial of Goal Management Training+ (GMT+) for methamphetamine use disorder.

Authors:  Alexandra C Anderson; Alex H Robinson; Dan I Lubman; Antonio Verdejo-Garcia
Journal:  Contemp Clin Trials Commun       Date:  2022-08-11

7.  Patterns of smoking and injecting methamphetamine and their association with health and social outcomes.

Authors:  Rebecca McKetin; Rachel Sutherland; Amy Peacock; Michael Farrell; Louisa Degenhardt
Journal:  Drug Alcohol Rev       Date:  2021-08-08

8.  The Identification of Precursor Regulation Impact on the Methamphetamine Market and Public Health Indicators in the Czech Republic: Time Series Structural Break Analysis.

Authors:  Benjamin Petruželka; Miroslav Barták
Journal:  Int J Environ Res Public Health       Date:  2020-10-26       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.